Iteos Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
iTeos Therapeutics, Inc. reported the immediate resignation of Tim Van Hauwermeiren from its Board of Directors, effective June 1, 2025, explicitly stating no disagreements with the company or its management.
iTeos Therapeutics, Inc. has filed a definitive proxy statement with the SEC.
iTeos Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 17, 2025, to elect directors and ratify the appointment of its independent accounting firm.
iTeos Therapeutics, Inc. has filed a definitive proxy statement with the SEC regarding its upcoming shareholder meeting.
iTeos Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, to vote on the election of Class I directors and the ratification of its independent accounting firm.